UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~September 1511, 2020

Yew Bio-Pharm Group, Inc.

(Exact name of registrant as specified in its charter)

Nevada

000-54701

26-1579105

(State or other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

9460 Telstar Avenue, Suite 6

El Monte, California

91731

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (626)-401-9588

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		YEWB		OTC Markets Group

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ~~Emerging growth company. ☐~~

Emerging growth company. ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~SAFE ~~8.01~~HARBOR ~~Other~~STATEMENT ~~Events~~UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

~~The~~Information ~~Corporation~~included isin ~~unable~~this toForm ~~meet~~8-K ~~the~~may ~~filing~~contain ~~deadline~~forward-looking ~~for~~statements within the ~~filing~~meaning of ~~its~~Section ~~Form~~27A ~~10-Q~~of ~~for~~the Securities Act and Section 21E of the ~~quarter~~Securities ~~ended~~Exchange ~~March~~Act of 311934, ~~2020~~as ~~due~~amended (the “Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to ~~circumstances~~as ~~related~~the “Company” or “Registrant”), to ~~COVID~~be materially different from future results, performance or achievements expressed or implied by any forward-19looking statements. ~~Most~~Forward-looking of statements, which involve assumptions and describe the Company’s ~~business~~future plans, isstrategies ~~in China~~ and soexpectations, isare ~~its~~generally ~~corporate~~identifiable ~~office.~~by ~~Some~~use of ~~its~~the ~~businesses~~words ~~and~~“may,” ~~offices~~“will,” ~~were~~“should,” “expect,” ~~closed~~“anticipate,” ~~upon~~“estimate,” ~~orders~~“believe,” “intend” or “project” ofor the ~~local~~negative ~~governments~~of these words or other variations on these words or comparable terminology. ~~Employees~~Forward-looking statements are ~~prohibited~~based on ~~from~~assumptions ~~going~~that ~~into~~may ~~work~~be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. InThe ~~view~~Company’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of ~~these~~various ~~circumstances~~factors. Except as required by applicable laws, wethe ~~are~~Company ~~unable~~undertakes no obligation to ~~provide our~~update ~~auditors~~publicly ~~and~~any ~~accountants~~forward-looking ~~with~~statements upfor toany ~~date~~reason, ~~financial~~even ~~records~~if new information becomes available or other events occur in the future.

OnItem ~~March 4, 2020, the U~~5.S.02 ~~Securities~~Departure ~~and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318)~~ of ~~the~~Directors ~~Securities~~or ~~Exchange~~Certain ~~Act~~Officers; ofElection ~~1934, as amended (“Exchange Act”), granting exemptions from specified provisions~~ of ~~the~~Directors; ~~Exchange~~Appointment Act and certain rules thereunder. On March 25, 2020, the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of ~~the~~Certain ~~novel~~Officers; ~~coronavirus~~Compensatory ~~(“COVID-19”)~~Arrangements ~~outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements~~ of ~~Exchange~~Certain Act Section 13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.Officers

~~The~~Resignation ~~Corporation is relying on SEC Releases No. 34-88318 and No. 34-88465 to delay the filing~~ of its Form 10-Q for the quarter ended March 31, 2020 for an extension on the filing due date to 45 days after the original due date which is May 15, 2020, and will work diligently to comply with such requirements.Director

~~SAFE~~On ~~HARBOR~~September ~~STATEMENT~~11, ~~UNDER~~2020, ~~THE~~Mrs. ~~PRIVATE~~Chang ~~SECURITIES~~Liu and Mr. ~~LITIGATION~~Hengjiang ~~REFORM~~Pang ~~ACT~~resigned OFas ~~1995~~Directors of the Company, in order to pursue other interests and businesses. The Company thanks Mrs. Liu and Mr. Pang for their service to the Company and wishes them the best in their future endeavors. There were no adverse reasons for their resignations.

~~Information~~The ~~included~~openings inwill this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to as the “Company” or “Registrant”), to be ~~materially~~filled ~~different from future results, performance or achievements expressed or implied~~ by ~~any forward-looking statements. Forward-looking statements, which involve assumptions and describe~~ the ~~Company’s~~Board ~~future~~after ~~plans,~~its ~~strategies~~due ~~and~~diligence ~~expectations,~~regarding ~~are generally identifiable by use of~~ the ~~words~~selection ~~"may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology~~process. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

Signature(s)

Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.

	Yew Bio-Pharm Group, Inc.
Date: May 15, 2020	By:	/s/ Zhiguo Wang
Date: September 15, 2020	By:	/s/ Zhiguo Wang
		Zhiguo Wang
		President & Chief Executive Officer

Filing Compare · Yew Bio-Pharm Group, Inc.